Over the last few years, there has been much discussion around VLA1553, a Chikungunya virus vaccine candidate. The vaccine has so far earned Fast Track and Breakthrough Therapy designations within the United States, as well as PRIME designation in Europe. Now, shares European Pharmaceutical Review, Phase 3 clinical trial data has further highlighted the efficacy of this vaccination. 

According to biotechnology and specialty vaccine company Valneva, VLA1553 is currently the most advanced Chikungunya vaccine candidate on a global scale. It confers protection against the viral, mosquito-borne illness through a single intramuscularly-administered shot. Researchers evaluated the safety, efficacy, and immunogenicity of the virus within the Phase 3 VLA1553-301 clinical trial. Altogether, over 4,000 adult patients enrolled. 

Researchers found that the vaccine was highly immunogenic in older patients (aged 65+) who were able to receive the same amount of neutralizing antibodies and protection as younger individuals. Around 98.9% of people achieved highly protective neutralizing antibody levels within one month of the vaccine, while 96.3% still showed protective qualities within 6 months. Researchers hope to continue monitoring patients to determine how durable and sustained the vaccine actually is. 

The vaccine was also relatively safe and well-tolerated. Some side effects included headache, fever, fatigue, and muscle pain. 

Moving forward, Valneva hopes to begin submitting VLA1553 for approval within the United States. 

About Chikungunya Virus

As described above, Chikungunya is a viral illness spread through the bites of infected Aedes mosquitos. It is most prevalent in Asia, Africa, Europe, and areas around the Indian and Pacific Oceans, though it has also been found in the Caribbean. There are currently no approved vaccines that protect against Chikungunya. Therefore, the best way to avoid this viral illness is to avoid being bitten by mosquitos. 

Up to 92% of people bitten by infected mosquitoes will experience symptoms. Typically, symptoms manifest within 3-7 days following infection. Symptoms are not usually fatal and will usually go away after a week or so. However, during the symptomatic period, these symptoms can be debilitating. Potential symptoms include:

• Fever
• Rash
• Joint pain and inflammation
• Muscle pain
• Headache
• Nausea

Learn more about Chikungunya virus.